Peter Lunder Joins Company's Business Advisory Board
YONKERS, N.Y., Jan. 24 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced the establishment of a
Scientific Advisory Board that will bring broad-ranging scientific expertise
to the Company. The initial members of the Scientific Advisory Board are Dr.
George P. Canellos (Harvard Medical School and Dana-Farber Cancer Institute),
Dr. Michael Harris (Tomorrows Children's Institute for Cancer and Blood
Disorders and UMDNJ-New Jersey Medical School), Dr. James D'Olimpio (North
Shore University Hospital and New York University School of Medicine) and Ms.
Carol Armenti (Center for Cervical Health).
"These world-class medical scientists, who bring expertise in the areas of
Oncology, Hematology and Women's Health Care, join ADVR at a pivotal period in
the growth of our Company. We will look to the members of our Scientific
Advisory Board to provide our scientists with additional expertise and counsel
to support the development of our flagship drug, Product R," said Shalom Z.
Hirschman, M.D., President and CEO of Advanced Viral Research Corp. "As we
prepare to undertake the scientifically rigorous clinical trials necessary to
successfully complete FDA's regulatory approval process, the Scientific
Advisory Board's expertise will be invaluable. We believe the Scientific
Advisory Board will help us to effectively bring our product to the forefront
of the biotechnology arena by advising us in researching the rich chemistry
and pharmacology of peptide-nucleic acids represented by Product R."
Dr. George P. Canellos is the William Rosenberg Professor of Medicine at
Harvard Medical School where he served as Chief of the Division of Medical
Oncology for 20 years at the renowned Dana-Farber Cancer Institute. Dr.
Canellos brings a wealth of knowledge to the Company through his previous
experience as Acting Clinical Director of the National Cancer Institute (NCI)
and his role as a member of the FDA's Oncologic Drugs Advisory Committee. Dr.
Canellos was also a past president of the American Society for Clinical
Oncology and a former Editor-in-Chief of the Journal of Clinical Oncology.
Dr. Canellos currently serves as Medical Director for Network Development,
Dana-Farber/Partners CancerCare and is on the senior staff at the Brigham and
Women's Hospital, Dana-Farber Cancer Institute and Massachusetts General
Hospital.
Dr. Michael Harris is Director of the famed Tomorrows Children's Institute
for Cancer and Blood Disorders, Chief of Pediatric Hematology-Oncology at the
Hackensack University Medical Center and Professor of Pediatrics at the
UMDNJ-New Jersey Medical School. Additionally, Dr. Harris is a member of the
National Cancer Institute's Special Review Committee where he is responsible
for the review of Community Clinical Oncology Programs, and Associate Editor
for Pediatric Oncology for the scientific journal Cancer Investigation. Dr.
Harris previously served as Chief of Pediatric Hematology-Oncology at The Mt.
Sinai Medical Center in New York City.
Dr. James D'Olimpio is Director of the North Shore University Hospital's
Supportive Oncology and Palliative Care Service and is also Associate
Professor of Medical Oncology at New York University's School of Medicine. His
research has focused on improving the quality of life of cancer patients,
especially by reversing the wasting process (cachexia) associated with cancer,
and in cancer treatment related fatigue syndrome.
Ms. Carol Armenti is the founder and Executive Director of the Center for
Cervical Health, a patient advocacy organization primarily devoted to cervical
health issues in the U.S. Recognized as an important figure in the advocacy
of women's health care, Ms. Armenti serves on key advisory boards, such as the
FDA and other governmental consulting boards, and is a noted lecturer on
women's health issues.
Peter Lunder Joins Business Advisory Board
Advanced Viral Research Corp. also announced that it has expanded its
Business Advisory Board with the addition of Mr. Peter Lunder. Mr. Lunder is
the former Co-Chairman and Treasurer of the Dexter Shoe Company (now owned by
Berkshire-Hathaway). In addition to his extensive business expertise, Mr.
Lunder has strong philanthropic interests in academic healthcare institutions,
and serves as a Regent of the Smithsonian Museum, the Governing Board Chairman
of Colby College's Museum of Art, and a member of the Dana-Farber Cancer
Institute's Visiting Committee.
"Mr. Lunder's extensive management expertise further broadens the pool of
business management and marketing experience that Advanced Viral can draw upon
as we work toward the commercialization of Product R," said Dr. Hirschman.
"In addition, Mr. Lunder brings strong relationships and philanthropic
interests across a variety of prestigious academic and healthcare institutions
to the Business Advisory Board."
The Business Advisory Board was formed in December 2001 to provide the
Company with expertise in international finance, strategic management and
business opportunities. The Business Advisory Board also includes Albert
Reichmann (co-founder, Olympia and York Developments Limited) and Dr. Jozef
Straus (CEO, JDS Uniphase Corporation).
Product R is being investigated as a non-toxic peptide-nucleic acid-type
immunomodulator that appears to stimulate the proinflammatory responses
required to combat viral infections such as AIDS and human papilloma virus and
to dampen aberrant autoimmune-type inflammatory responses, such as occur in
patients with rheumatoid arthritis. Therefore, Product R has been termed a
"switch type" immunomodulator. Product R is also being studied for the
promise shown in its ability to mitigate the toxic side effects of other
drugs, including those used to treat HIV infection and chemotherapeutic drugs
employed in the treatment of cancers.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm committed to researching, developing and bringing to
market new effective therapies for viral and other diseases.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. Product R is not
approved by the FDA or any comparable agency of any other country. There is
no assurance that the Company will be able to secure the financing necessary
to complete the clinical trials of Product R. The Company undertakes no
obligation to update or revise the information contained in this announcement
whether as a result of new information, future events, circumstances or
otherwise.
Contact Information:
Mayr Communications, Inc.
877-777-6010
mayrcomm@att.net
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
CONTACT:
Mayr Communications, Inc., +1-877-777-6010,
mayrcomm@att.net, for Advanced Viral Research Corp.
|
